ClinicalTrials.gov
public full text
Public Domain
PET Whole Body Distribution Studies Using [11C]CUMI
Background: * Researchers studying new treatments for major depressive disorder are looking at how medications to treat depression act on the brain chemical serotonin, which interacts with specific serotonin receptors on brain cells. New methods of studying serotonin receptors in the brain may help provide a better understanding of depression and treatment options. * A new radioactive chemical called \[11C\]CUMI may be useful for studying serotonin receptors in the brain. By using positron emission tomography (PET) scanning to see how \[11C\]CUMI bonds with serotonin receptors, researchers will investigate whether \[11C\]CUMI can be used to study depression and how antidepressant medications work. Objectives: \- To determine the usefulness of \[11C\]CUMI as a method of studying serotonin receptors in the brain. Eligibility: \- Healthy individuals between 18 and 65 who have no history of psychiatric illness. Design: * This study requires 8 outpatient visits to the NIH clinic. * Visit 1: Participants will have a full physical examination and medical history, as well as a psychiatric evaluation and questions about alcohol and drug use. Other tests will include blood and urine samples and an electrocardiogram (EKG). Testing will take approximately 3 hours. * Visit 2: Participants will have a magnetic resonance imaging (MRI) scan to evaluate brain function and activity. * Visit 3: Participants will have a PET scan, in which a small amount of the radioactive chemical \[11C\]CUMI will be injected through an intravenous (IV) catheter, and will have another IV line put in place to draw regular blood samples during the scan. The scan will last approximately 4 hours. * Visits 4-8: Participants will have regular blood tests after the scan between days 1-3 and at about weeks 1, 2, 3, and 4. The blood tests will check muscle, heart, and liver function.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study#1094927
- Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy#980747
- PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing#841596
- A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia#1163218
- 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder#1153362
Record · ID 877829
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive